<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><meta http-equiv="Content-Language" content="en" /><title>Verbatim report of proceedings - Patenting of human genes - Thursday, 4 October 2001</title><meta name="title" content="Verbatim report of proceedings - Patenting of human genes - Thursday, 4 October 2001" /><meta name="language" content="en" /><meta name="robots" content="index, follow, noodp, noydir, notranslate" /><meta name="copyright" content="© European Union, 2001 - Source: European Parliament" /><meta name="available" content="04-10-2001" /><meta name="sipade-leg" content="5" /><meta name="sipade-type" content="CRE" /><meta property="og:title" content="Verbatim report of proceedings - Patenting of human genes - Thursday, 4 October 2001" /><meta property="og:image" content="https://www.europarl.europa.eu/website/common/img/icon/sharelogo_facebook.jpg" /><link rel="canonical" href="https://www.europarl.europa.eu/doceo/document/CRE-5-2001-10-04-ITM-009_EN.html" /><link href="/doceo/data/css/style_common.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_common_print.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_sipade.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_activities.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/common_sides.css" type="text/css" rel="stylesheet" /><link href="/doceo/data/css/style_sipade_oj_sched.css" type="text/css" rel="stylesheet" />
<script src="/doceo/data/js/overlib.js" type="text/javascript"> </script>
<script src="/doceo/data/js/swap_images.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade.js" type="text/javascript"> </script>
<script src="/doceo/data/js/jquery-1.4.4.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade-OJ-SYN.js" type="text/javascript"> </script><!--ATI analytics script--><script type="text/javascript" data-tracker-name="ATInternet" defer data-value="/website/webanalytics/ati-doceo.js" src="//www.europarl.europa.eu/website/privacy-policy/privacy-policy.js" ></script></head><body bgcolor="#FFFFFF"><div id="overDiv" style="position:absolute; visibility:hidden; z-index:1000;"> </div><a name="top"></a><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td><div id="header_sides" class="new">
<a href="/portal/en"><img alt="Go back to the Europarl portal" title="Go back to the Europarl portal" src="/doceo/data/img/EP_logo_neg_EN.png" /></a><h3 class="ep_hidden">Choisissez la langue de votre document :</h3><ul class="language_select">
            <li class="bg" title="bg - български">bg - български</li>
            <li><a title="es - español" class="es on" href="/doceo/document/CRE-5-2001-10-04-ITM-009_ES.html">es - español</a></li>
            <li class="cs" title="cs - čeština">cs - čeština</li>
            <li><a title="da - dansk" class="da on" href="/doceo/document/CRE-5-2001-10-04-ITM-009_DA.html">da - dansk</a></li>
            <li><a title="de - Deutsch" class="de on" href="/doceo/document/CRE-5-2001-10-04-ITM-009_DE.html">de - Deutsch</a></li>
            <li class="et" title="et - eesti keel">et - eesti keel</li>
            <li><a title="el - ελληνικά" class="el on" href="/doceo/document/CRE-5-2001-10-04-ITM-009_EL.html">el - ελληνικά</a></li>
            <li class="en selected" title="en - English">en - English<span> (Selected)</span></li>
            <li><a title="fr - français" class="fr on" href="/doceo/document/CRE-5-2001-10-04-ITM-009_FR.html">fr - français</a></li>
            <li class="ga" title="ga - Gaeilge">ga - Gaeilge</li>
            <li class="hr" title="hr - hrvatski">hr - hrvatski</li>
            <li><a title="it - italiano" class="it on" href="/doceo/document/CRE-5-2001-10-04-ITM-009_IT.html">it - italiano</a></li>
            <li class="lv" title="lv - latviešu valoda">lv - latviešu valoda</li>
            <li class="lt" title="lt - lietuvių kalba">lt - lietuvių kalba</li>
            <li class="hu" title="hu - magyar">hu - magyar</li>
            <li class="mt" title="mt - Malti">mt - Malti</li>
            <li><a title="nl - Nederlands" class="nl on" href="/doceo/document/CRE-5-2001-10-04-ITM-009_NL.html">nl - Nederlands</a></li>
            <li class="pl" title="pl - polski">pl - polski</li>
            <li><a title="pt - português" class="pt on" href="/doceo/document/CRE-5-2001-10-04-ITM-009_PT.html">pt - português</a></li>
            <li class="ro" title="ro - română">ro - română</li>
            <li class="sk" title="sk - slovenčina">sk - slovenčina</li>
            <li class="sl" title="sl - slovenščina">sl - slovenščina</li>
            <li><a title="fi - suomi" class="fi on" href="/doceo/document/CRE-5-2001-10-04-ITM-009_FI.html">fi - suomi</a></li>
            <li><a title="sv - svenska" class="sv on" href="/doceo/document/CRE-5-2001-10-04-ITM-009_SV.html">sv - svenska</a></li>
        </ul></div></td></tr><tr><td style="padding:10px;"><table width="100%" border="0" cellspacing="0" cellpadding="0"><tr><td><table border="0" align="left" cellpadding="0" cellspacing="0"><tr><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-5-2001-10-04-TOC_EN.html"><img src="/doceo/data/img/navi_index.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-5-2001-10-04-TOC_EN.html" title="Index">Index</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-5-2001-10-04-ITM-008_EN.html"><img src="/doceo/data/img/navi_previous.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-5-2001-10-04-ITM-008_EN.html" title="Previous">Previous</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td valign="middle"> <a href="/doceo/document/CRE-5-2001-10-04-ITM-010_EN.html" title="Next">Next</a> </td><td><a href="/doceo/document/CRE-5-2001-10-04-ITM-010_EN.html"><img src="/doceo/data/img/navi_next.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-5-2001-10-04_EN.html"><img src="/doceo/data/img/navi_moredetails.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-5-2001-10-04_EN.html" title="Full text">Full text</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td></tr><tr><td><img src="/doceo/data/img/spacer.gif" width="10" height="15" alt="" /></td></tr></table></td></tr></table><table width="100%" border="0" cellpadding="5" cellspacing="0" class="doc_box_header">
<tr>
<td align="left" valign="top" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="title_TA">Verbatim report of proceedings</td><td valign="top" align="right" style="background-image:url(/doceo/data/img/gradient_blue.gif)"></td>
</tr>
<tr>
<td class="doc_title" align="left" valign="top" bgcolor="#F5F5F5">Thursday, 4 October 2001 - Strasbourg</td>
<td class="doc_title" align="right" valign="top" bgcolor="#F5F5F5">OJ edition</td></tr></table><br />
<table width="100%" border="0" cellpadding="0" cellspacing="0" class="doc_box_header" style="padding-bottom:5px"><tr valign="top"><td>
<table width="100%" border="0" cellpadding="5" cellspacing="0"><tr valign="top" style="padding-bottom:0px;padding-left:5px;padding-right:5px;padding-top:5px"><td align="left" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="doc_title"><img src="/doceo/data/img/arrow_title_doc.gif" width="8" height="14" border="0" align="absmiddle" alt="" /> 9. Patenting of human genes</td></tr></table>
<a name="4-179"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1364.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">President.</span></span>   –<span class="bold"> </span>The next item is the joint debate on the following motions for resolutions:</p>
<p class="contents">- <a href="/doceo/document/B-5-2001-0633_EN.html">B5-0633/2001</a> by Mrs Oomen-Ruijten and others, on behalf of the PPE-DE Group, on the human gene register BRCA1 and BRCA2 (breast cancer);</p>
<p class="contents">- <a href="/doceo/document/B-5-2001-0641_EN.html">B5-0641/2001</a> by Mr Ribeiro e Castro, on behalf of the UEN Group, on the human gene register BRCA1 and BRCA2 (breast cancer);</p>
<p class="contents">- <a href="/doceo/document/B-5-2001-0651_EN.html">B5-0651/2001</a> by Mr Gebhardt and Mr Paciotti, on behalf of the PSE Group, on the human gene register;</p>
<p class="contents">- <a href="/doceo/document/B-5-2001-0663_EN.html">B5-0663/2001</a> by Mr Lannoye and others, on behalf of the Verts/ALE Group, on the human gene register; </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-180"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1122.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Oomen-Ruijten (PPE-DE).</span></span>   – <span class="italic">(NL)</span> Mr President, I regret that I must remain seated. On 30 March last year, Parliament declared that people and their genes or cells in a natural environment cannot be patented. However, if a patent is granted to Myriad Genetics, this will create a monopoly situation for one particular company. This means that there is a danger that certain genetic tests and some of the DNA diagnostic tests in Europe will be commercialised.</p>
<p class="contents">Three applications for patents on sequences and applications of a breast cancer gene have now been accepted by the European Patent Office. Applications from Myriad for patents on the BRCA2 gene are still being processed. If these patents are awarded, this US company will have a monopoly on the BRCA gene and consequently on the DNA test. This means that abnormalities in patients from families with a history of breast cancer and ovarian cancer will only be able to be detected with this American test. If Myriad is going to use a similar system in Europe to the one it uses in the United States, the samples from all future laboratory tests will have to be sent to the United States, which will also be very expensive if the analyses have to be done there.</p>
<p class="contents">This means that there is a danger that a monopoly may be created, which will put the quality of European diagnostics at risk. It also means that the availability of data for analysis purposes and the development of new diagnostic applications in our own molecular and testing laboratories will be limited, which will push up the cost of breast cancer screening and therefore of health insurance.</p>
<p class="contents">Not only Parliament but also everyone in society who is involved in this has registered objections in this regard. We therefore ask for this monopoly position, which is in nobody's interest, to be opposed and the patent application to be rejected. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-181"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1913.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Gebhardt (PSE).</span></span>   – <span class="italic">(DE)</span> Mr President, Commissioner, ladies and gentlemen, it will not only horrify a great many women to see that a US company, through the patenting process, has effectively acquired ownership of 'breast cancer genes'. The fact that in the race for money and profit, a great many people's health is put at risk is enough to make anyone's blood run cold. Yet this is exactly what threatens to occur following the award of patents on the BRCA 1 and BRCA 2 genes. As a worst-case scenario, many patients may face delays in the early detection of breast cancer as a result of these patent awards. Yet with this type of cancer in particular, early detection is crucial to increase the chances of recovery. Furthermore, the virtual monopoly on test methods pushes costs so high that early detection of breast cancer is no longer available to many women.</p>
<p class="contents">Nor should we ignore the extent to which the BRCA patents are impeding research in Europe. One of the leading cancer research institutes – the <span class="italic">Institut Curie </span>in Paris – has highlighted this situation and provided impressive and conclusive proof.</p>
<p class="contents">It is very welcome that this prestigious research institute has taken action and, with the support of the French Ministry of Health, is initiating an opposition procedure to the patent award. This House will certainly not be making a mistake if it supports this position. A welcome step would be to call upon the responsible agencies to lodge immediate appeals against the award of the BRCA patents with the European Patent Office in Munich. It is also important that we should appeal to the institutions and governments of the EU Member States to lodge similar appeals as a matter of urgency. We owe this to the women affected. This is the least we can do for them at this point. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-182"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1059.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Breyer (Verts/ALE).</span></span>   – <span class="italic">(DE)</span> Mr President, ladies and gentlemen, next Tuesday, in response to an application by the Netherlands which is supported by Italy and Norway, the ECJ will decide on the Patent Directive's compatibility with the Treaty. Today, the European Parliament, through its vote, will decide between the reality and the Directive. The BRCA patents in particular make it clear that the price of medicines is being increased unnecessarily and that monopolies are being created which impede effective diagnosis and therapy and block research into new and useful drugs.</p>
<p class="contents">The time has come for the Commission – and I call upon the Commissioner present to make a statement on this issue – to put an end to the conflicts surrounding the interpretation of this Directive, either by amending the Directive or adopting guidelines. In my view, the Commission should not bury its head in the sand and say, well, we know that many Member States have problems with this Directive because they do not know how to apply it; we know that the European Patent Office interprets it in a particular way. I therefore urge you to make a statement on this issue.</p>
<p class="contents">The human body must not be degraded to biological material. Human genes or living organisms or elements thereof must not be subject to patent law. A discovery must not be recast as an invention. We must prevent monopolies on human genes impeding research into new and useful drugs. We cannot stand and watch the early detection of breast cancer falling by the wayside simply because patent rights are to be created for something which is not an invention but, at the very most, a discovery. Action is required not only by the European Parliament – we have, I believe, made it quite clear with this resolution that we are not prepared to stand and watch – but also by the Commission and the Member States. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-183"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1247.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Rothley (PSE).</span></span>   – <span class="italic">(DE) </span>Mr President, I shall not speak about the subject but on the institutional issues. This House has already rejected the option of – or, at least, it has refrained from – lodging an appeal with the European Patent Office. That is only right and proper. The European Parliament is a legislative body, and as a legislative body, it cannot intervene in current proceedings. That is simply not possible! This is one of the fundamental principles of a democracy under the rule of law.</p>
<p class="contents">The legislator passes a law – in this case, the Directive – which will be confirmed next week by the European Court of Justice. Then it will be down to the authorities to apply the Directive and award a patent or not, and the courts will have to decide whether this award or refusal of a patent is lawful. That is the due process, and no other process exists in a democracy under the rule of law. That is why the legislator – in this case, the European Parliament – cannot intervene in current proceedings.</p>
<p class="contents">The European Parliament has about as much responsibility for this issue as the Commission, or the Green Party congress or a general meeting of Greenpeace. It is not for the Commission, or this House, or the Greens, or Greenpeace to decide how a Directive should be applied; that is the task of the relevant authorities. They – and the courts – decide on this issue, nobody else! And that is how it should be.</p>
<p class="contents">Other than that, Ms Breyer, almost everything you said was factually incorrect. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-184"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/2305.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Thors (ELDR).</span></span>   <span class="italic">(SV) </span>Mr President, Commissioner, the Group of the European Liberal, Democrat and Reform Party is against the patenting of human genes as such, something we also stated in 1998 when Parliament adopted the Directive on the legal protection of biotechnological inventions. However, we believe that the directive does not allow patents for genes as such, if they do not contain an invention, and we supported the directive when it was adopted. We believe that the fact that, in a debate on topical and urgent subjects, we are now discussing a resolution on certain patents constitutes an abuse. We have therefore not signed the common resolution.</p>
<p class="contents">Although we have a Temporary Committee on Human Genetics, where the question of patents constitutes one of the most important issues, the issue of patents is being brought up here so that a general position might be adopted on the matter, and I would like to repeat that this is very wrong. We really believe that this is an abuse. There have been no formal opportunities to raise objections, but we believe that Parliament’s rules should be changed. The fact that just a few people are to discuss the issue quickly here is therefore very wrong.</p>
<p class="contents">We also believe that the draft resolution is not entirely correct. The patent applications which exist, and I have a summary of them here, expressly state that they apply to methods and not to genes as such. You are attempting to give the impression that the European Patent Office is now about to approve patents on human genes, and this is not the case.</p>
<p class="contents">However, there is one point on which we can agree with those who drew up the proposal, and that is that in certain respects the patents are two ‘broad’. This means that we should review issues such as compulsory licences with an eye to research and public health. Unfortunately, this is not something that can be dealt with at Community level, but is the responsibility of the Member States.</p>
<p class="contents">I hope that we can discuss the issue of licences in peace and quiet in the Committee on Human Genetics. We shall not be able to support the resolution. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-185"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/729.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Purvis (PPE-DE).</span></span>   – Mr President, while Mrs Thors was speaking the Commissioner was interrupted by two different people, so he was not paying attention to what she asked and what she said. It was vitally important to me, as someone trying to learn from this debate, to ascertain the facts of the situation. I was very interested in what Mr Rothley and Mrs Thors said as to whether we should even be discussing this issue in this Chamber. But Mr Nielson was otherwise distracted. I would hope that he gives us a proper response when his turn comes to speak. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-186"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1364.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">President.</span></span>   –<span class="bold"> </span>Thank you very much, Mr Purvis. The issue of whether or not Mr Nielson was distracted is something we will be able to decide on at the end of the debate. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-187"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1059.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Breyer (Verts/ALE).</span></span>   – <span class="italic">(DE) </span>Mr President, the previous speaker made a comment. I think that Mr Rothley attacked me personally. I would like to make it clear once again that the European Patent Office does not have a court. It has a Board of Appeal. That is a significant difference. I say this so that our colleague is properly informed. It is quite clear that the patent refers to genes – indeed, to mutated genes – and to the analysis procedure, for the sake of accuracy. I would recommend that any Members of this House who are interested should visit the website of the <span class="italic">Institut Curie</span> in France – the prestigious research institute which has initiated an opposition procedure – as this describes the situation in detail. It is indeed a fact that only an invention may be patented, not a discovery.</p>
<p class="contents">On Ms Thors' objection regarding the urgency: the deadline set for instituting proceedings against the first patent expires on Tuesday. This means that we cannot wait for the Fiori report, which will not be discussed until the October II part-session. What Mr Rothley says is also incorrect. We are indeed a legislative body, but his own Minister of Justice in Germany, Ms Däubler-Gmelin, once applied this procedure. Even the Federal Government once appealed against a patent which had been awarded by the Patent Office in 1999. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-188"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1969.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Blokland (EDD).</span></span>   – <span class="italic">(NL)</span> Mr President, once again there are problems with a patent granted by the European Patent Office. In March 2000 we discussed a patent for the manipulation of human cells and embryos; now we are confronted with a patent on human breast cancer genes.</p>
<p class="contents">Let me make it clear – and I repeat what I said earlier, including in speeches on Directive 98/44/EC on the legal protection of biotechnological inventions – a patent can and may only be obtained or granted for an invention and not for a discovery.</p>
<p class="contents">I urge the European Patent Office to adhere to this. Otherwise the entire human genome will be patented in the not too distant future! And what will the next step be: a modified cell, an organism? The mind boggles.</p>
<p class="contents">However, to get back to the patent on a breast cancer gene. So where does the problem actually lie? How can the European Patent Office grant a patent on a human gene? The answer is simple: because Directive 98/44/EC is being applied. Despite the well-known fact that only a few Member States have implemented this directive and in spite of the European Parliament's resolutions.</p>
<p class="contents">Why is Directive 98/44/EC so controversial? Let me explain again.</p>
<p class="contents">As a result of sloppy legislation, there is a contradiction in the directive. Let us not make it more complicated than it already is: Article 5.1 and Article 5.2 contradict each other. Article 5.1 reads: "The human body, at the various stages of its formation and development, and the simple discovery of one of its elements, including the sequence or partial sequence of a gene, cannot constitute patentable inventions." Article 5.2 reads: "An element isolated from the human body or otherwise produced by means of a technical process, including the sequence or partial sequence of a gene, may constitute a patentable invention, even if the structure of that element is identical to that of a natural element." In other words, Article 5.1 says that genes should not be patented, whilst Article 5.2 says that a gene can be patented if it is isolated or produced by means of a technical process. However, all genes used by scientists are produced by means of a technical process. Let us therefore do our utmost to eliminate this inconsistency from Directive 98/44/EC.</p>
<p class="contents">I am against the European Patent Office taking these steps, not only because a patent on a gene runs counter to the concept of patenting. Another important consideration is that I regard life in all its facets and parts as God's creation. This also convinces me that a gene cannot be patented.</p>
<p class="contents">In March 2000, I said that Directive 98/44/EC would continue to provoke discussion. After heated debates in the temporary committee on human genetics and after today I can indeed say that my prediction was correct. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-189"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1913.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Gebhardt (PSE).</span></span>   – <span class="italic">(DE) </span>Mr President, I will not go into the content again; I would just like to correct a statement which was made in error. I spoke for the Group of the Party of European Socialists, and what I said applies to our group. I just wanted to clarify that point. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-190"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/doceo/data/img/photo_generic.gif" align="right" width="50" height="63" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nielson,</span></span>   <span class="italic">Commission</span>. – The problem raised by the patents granted by the European Patent Office to Myriad Genetics does not appear to derive from the field of ethics. These patents highlight a technical question deriving from the field of patent law. The situation is thus completely different from that raised by the famous "Edinburgh patent".</p>
<p class="contents">The problem resides more in the extent of the protection to be granted to these patents. This question is highly complex since, as it applies to gene sequences, it undoubtedly involves a situation relating to competition and innovation, and in no way fundamental principles relating to the dignity or integrity of human beings. It should be noted that this patent is of undoubted interest for the scientific community. It should make it possible to improve the early detection of breast cancer in women.</p>
<p class="contents">The Commission considers there are no imperative reasons why the Commission should raise any objections, as the contested patent does not infringe essential ethical rules and concerns the field of application which can be granted to a patent relating to a DNA sequence. Nevertheless, the Commission will study the question of the field of protection for inventions relating to gene sequences in depth and will communicate its observations to the Council and Parliament in the reports provided for by Directive 98/44. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-191"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1122.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Oomen-Ruijten (PPE-DE).</span></span>   – <span class="italic">(NL)</span> I am utterly amazed that the Commission is not responding. Number one.</p>
<p class="contents">Secondly, I would ask the Commission whether it is in fact willing to do anything before 10 October. When I say a gene, I mean a gene sequence. According to the patent directive, a gene sequence cannot be patented. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-192"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1059.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Breyer (Verts/ALE).</span></span>   – <span class="italic">(DE) </span>Mr President, I vigorously endorse what Ms Oomen-Ruijten has said. Commissioner, you cannot take an infinite amount of time over this. I too expect that the Commission will state its position on this issue by 9 October. You said that there are no objections of an ethical nature, but that you will study the question of the field of protection for inventions. However, you have not answered the question put to you by myself, Mr Blokland, and others on whether Article 5.1 now applies in this context or whether Article 5.2 should take priority. I believe that many Members of this House expect the Commission to clarify this serious and very important issue. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-193"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1364.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">President.</span></span>   –<span class="bold"> </span>Thank you very much, Mrs Breyer. I would ask you to exercise a little discipline, because otherwise we will never finish this debate and we still have the voting time at 6.30 p.m. and two further reports to get through. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-194"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1247.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Rothley (PSE).</span></span>   – <span class="italic">(DE) </span>Mr President, naturally, I am referring to the procedure. I would like to thank the Commission for the explanation. I fully endorse its position. Please be assured that the Commission has the support of a large majority of Members of this House. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-195"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1913.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Gebhardt (PSE).</span></span>   – <span class="italic">(DE) </span>Mr President, this is a very serious matter. I call upon the Commission to study very carefully whether these patents which have been awarded genuinely comply with the Patent Directive, and not to act as if this House had no role in this area and were not entitled to adopt decisions. I hope that you will take serious steps to comply with the decisions which are about to be adopted by this House. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-196"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/doceo/data/img/photo_generic.gif" align="right" width="50" height="63" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nielson,</span></span>   <span class="italic">Commission</span>. – I will put your objections to my colleagues. I also want to point out that what I have said reflects the way the Commission services, and the Commission as such, analyse this issue. I will repeat what I just said: "the Commission considers there are no imperative reasons why it should raise any objections, as the contested patent does not infringe essential ethical rules and concerns the field of application which can be granted to a patent relating to a DNA sequence".</p>
<p class="contents">Obviously there is, and may continue to be, disagreement. This is the reality in an area like this, and ten years of discussions leading up to the 1998 directive may not be enough to create a real, workable agreement. However, this is the legislation we have as our basis for action. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-197"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1364.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">President.</span></span>   –<span class="bold"> </span>Thank you very much, Commissioner Nielson.</p>
<p class="contents">The debate is closed.</p>
<p class="contents">The vote will take place today, at 6.00 p.m. </p></td><td width="16"> </td></tr></table></td></tr></table><table width="100%" border="0" cellspacing="0" cellpadding="5"><tr class="footerdocwin"><td></td><td align="right"><a target="_blank" href="/legal-notice/en">Legal notice</a> - <a target="_blank" href="/privacy-policy/en">Privacy policy</a></td></tr></table></td></tr></table></body></html>
